<p>BioNTech Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly and said the company could file for US approval in mid-November if the data are positive.</p>.<p>"We will certainly be smarter in a fortnight," Sahin said in a video interview with regional publisher VRM posted online late on Thursday, adding he expects first efficacy data in late October, early November.</p>.<p>"We are optimistic," he said, adding if the data are positive, a request for emergency approval could be submitted to the US Food and Drug Administration (FDA) in mid-November.</p>.<p><strong>Also Read:<a href="https://www.deccanherald.com/international/world-news-politics/brazil-will-have-a-covid-19-vaccine-by-june-2021-says-regulator-908936.html"> Brazil will have a Covid-19 vaccine by June 2021, says regulator</a></strong></p>.<p>BioNTech and its US partner Pfizer are among the leading companies in the race to develop a coronavirus vaccine, along with the US biotech group Moderna and the British company AstraZeneca.</p>.<p>Pfizer said on Tuesday there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.</p>.<p>Pfizer also said that if the trial is successful, it expects to file for emergency authorization shortly after it has enough safety data in late November. </p>
<p>BioNTech Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly and said the company could file for US approval in mid-November if the data are positive.</p>.<p>"We will certainly be smarter in a fortnight," Sahin said in a video interview with regional publisher VRM posted online late on Thursday, adding he expects first efficacy data in late October, early November.</p>.<p>"We are optimistic," he said, adding if the data are positive, a request for emergency approval could be submitted to the US Food and Drug Administration (FDA) in mid-November.</p>.<p><strong>Also Read:<a href="https://www.deccanherald.com/international/world-news-politics/brazil-will-have-a-covid-19-vaccine-by-june-2021-says-regulator-908936.html"> Brazil will have a Covid-19 vaccine by June 2021, says regulator</a></strong></p>.<p>BioNTech and its US partner Pfizer are among the leading companies in the race to develop a coronavirus vaccine, along with the US biotech group Moderna and the British company AstraZeneca.</p>.<p>Pfizer said on Tuesday there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.</p>.<p>Pfizer also said that if the trial is successful, it expects to file for emergency authorization shortly after it has enough safety data in late November. </p>